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S1
Clinical Features and Evidence-Based Management of Graves’
Orbitopathy
Luigi Bartalena (luigi.bartalena@uninsubria.it)
Endocrine Unit, University of Insubria, Varese, Italy
Thyroid Research 2017, 10(Suppl 1):S1
Graves’ orbitopathy (GO) is the main extrathyroidal manifestation of
Graves’ disease. When fully expressed, it is characterized by inflam-
matory soft tissue changes, exophthalmos, ocular dysmotility causing
diplopia, and, rarely, sight-threatening dysthyroid optic neuropathy
(DON). The prevalence of GO among Graves’ patients seems lately
declining, probably due to early diagnosis, early intervention on risk
factors associated with its occurrence or progression (smoking,
uncontrolled thyroid dysfunction), early correction of hyper and
hypothyroidism. Only about 25–30% of newly diagnosed Graves’ hy-
perthyroids are affected with GO, which is usually mild and rarely
progressive. Assessment of activity and severity of GO according to
standardized criteria is fundamental to plan management. The
European Thyroid Association and the European Group on Graves’
Orbitopathy (EUGOGO) have recently published the first guideline on
management of GO. Mild GO usually requires only a watchful
strategy, in addition to local measures (eye drops, ointments) and
removal of risk factors. Intravenous glucocorticoids (ivGCs) are the
first-line treatment for moderate-to-severe and active GO, as demon-
strated by randomized clinical trials. When ivGCs fail or GO recurs
after treatment withdrawal, options include a second course of ivGCs,
oral GCs combined with orbital radiotherapy or cyclosporine, rituxi-
mab. Evidence that the any of the above treatment be effective in
the context of a poor response to a first course of ivGCs is limited
and should be investigated in larger studies. In addition to rituximab,
ongoing investigations are exploring the role of other biologics tar-
geting, e.g., the IGF-1 receptor or the IL-6 receptor, and results will
probably available in 1–2 years. When GO has been treated medically
and is inactive, rehabilitative surgery (orbital decompression, squint
surgery, eyelid surgery) is often needed.
S2
Role of T3 and TRH in the hypothalamic regulation of energy
metabolism
Eric Fliers (e.fliers@amc.uva.nl)
Department of Endocrinology and Metabolism at the Academic Medical
Center, University of Amsterdam, Amsterdam, Netherlands
Thyroid Research 2017, 10(Suppl 1):S2
The relation between thyrotoxicosis, the clinical syndrome resulting
from exposure to excessive thyroid hormone, and the autonomic
nervous system remains enigmatic. Recent experiments from our lab
and others have shown that T3 may act within several hypothalamic
nuclei to modulate hepatic glucose metabolism and brown adipose
tissue (BAT) activity. These effects are mediated via pre-autonomic
neurons connecting the paraventricular and ventromedial nuclei
(PVN and VMH) with these peripheral organs via neural pathways.
Intrahypothalamic effects of T3 on glucose metabolism in the liver
could be modulated by selective hepatic sympathetic and parasym-
pathetic denervation. Thyroid hormone appeared to stimulate hep-
atic glucose production via a sympathetic pathway, representing a
novel central route for thyroid hormone action. As most of the exper-
iments were performed in a rather acute setting we recently devel-
oped a model for chronic intrahypothalamic T3 administration in
rats, allowing for the assessment of chronic metabolic effects of intra-
hypothalamic T3 administration. In addition to T3, we now investi-
gate the role of intrahypothalamic TRH in energy metabolism.
Further elucidation of intrahypothalamic effects of thyroid hormones
on autonomic outflow to metabolic organs will add to our under-
standing of the metabolic effects of hyperthyroidism.
S3
Triiodothyronine, Deiodinase 3 and Stem Cell-derived
Cardiomyocyte Maturation
Nicola Hellen (n.hellen@imperial.ac.uk)
National Heart and Lung institute, Imperial College, London, UK
Thyroid Research 2017, 10(Suppl 1):S3
Functional cardiomyocytes can be derived from both human embry-
onic (hESCs) and induced pluripotent (hiPSCs) stem cells. These pluri-
potent stem cell-derived cardiomyocytes (hPSC-CM) hold great
potential for regenerative medicine and in vitro screening. However,
the phenotype is immature and more closely resembles that of
foetal/neonatal cardiomyocytes. In the adult heart thyroid hormone
has pleiotropic effects on contractility and energy metabolism. The
active form of thyroid hormone, triiodothyronine (T3), is known to
play a role during foetal cardiomyocyte maturation and has recently
been shown to promote cardiac differentiation and enhance hPSC-
CM maturation in vitro. During development the enzyme, deiodinase
3 (D3), protects the foetus against maternal thyroid hormone by
metabolism of T3 into inactive products. Down regulation of D3 at
appropriate times during development allows physiological growth
and maturation of cardiomyocytes in response to thyroid hormone.
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We show that stimulation of the thyroid hormone pathway can
enhance the maturation of hPSC-CM and that further investigation
into the contribution of individual components of this pathway is
warranted.
O1
Controlled Antenatal Thyroid Study: Obstetric Outcomes
Peter N Taylor1, Arron Lacey2, Daniel Thayer2, Mohd Draman Yusof1,
Arshiya Tabasum1, Illaria Muller1, Luke Marsh1, Marian Ludgate1,
Alex Rees3, Kristien Boelaert4, Shiao Chan5, Scott Nelson6, Aled Rees1,
John H Lazarus1, Colin M Dayan1, Bijay Vaidya7, Onyebuchi Okosieme1
1Thyroid Research Group, School of Medicine, Cardiff University, Cardiff,
UK; 2Secure Anonymised Information Linkage (SAIL) Databank, Swansea
University, Swansea, UK; 3Obstetrics and Gynaecology Department,
University Hospital Wales, Cardiff, UK; 4University of Birmingham and
Queen Elizabeth Hospital, Birmingham, UK; 5Department of Obstetrics
and Gynaecology, National University of Singapore, Singapore,
Singapore; 6Obstetrics & Gynaecology Department, University of
Glasgow, Glasgow, UK; 7Department of Endocrinology, Royal Devon and
Exeter NHS Foundation Trust, Exeter, UK
Correspondence: Peter N Taylor (TaylorPN@Cardiff.ac.uk)
Thyroid Research 2017, 10(Suppl 1):O1
Background
Suboptimal thyroid function in pregnancy is associated with adverse
obstetric outcomes but it is unclear whether levothyroxine treatment,
initiated during pregnancy is beneficial. We investigated whether
correction of abnormal thyroid function during pregnancy is associ-
ated with improved obstetric outcomes.
Methods
Retrospective analysis of the Controlled Antenatal Thyroid Screening
(CATS) study with obstetric outcomes obtained through data-linkage
in the Secure Anonymised Information Linkage (SAIL) databank. Set-
ting: Welsh participants from CATS. Participants: 13,506 pregnant
women; 12,874 women had normal thyroid function, 320 had sub-
clinical hypothyroidism (SCH), 281 had isolated hypothyroxinemia
(IH) and 31 had overt hypothyroidism. Main Outcome Measures:
Odds of stillbirths (fetal demise after 24 weeks gestation), Caesarean
sections, prematurity and abnormal birth-weight by thyroid and
treatment status.
Results
Untreated women with SCH had increased odds of stillbirth com-
pared to women with normal thyroid function OR = 5.73 (95%CI 1.74,
18.9) p = 0.003. No stillbirths occurred in women receiving levothyr-
oxine. In analysis of women with IH, untreated women had an in-
creased risk of early (≤37 weeks) caesarean section than those who
received levothyroxine (6% vs 0%) p = 0.006. Untreated women with
IH also had earlier mean gestational age 38.8 (SD 2.34) weeks vs.
39.7 (SD 1.94) weeks p = 0.002 and lower mean birth-weight 3353 g
(SD 639) vs. 3558 g (SD 532) p = 0.004.
Conclusion
Both SCH and IH are associated with adverse obstetric outcomes. In
IH levothyroxine treatment is associated with favourable effects on,
gestational age at delivery and early Caesarean section rates.
Levothyroxine may also have some protective impact on stillbirths in
SCH.
O2
Pharmacological enhancement of radioiodine uptake using Src
kinase inhibitors
Vikki L. Poole, Alice Fletcher, Bhavika Modasia, Neil Sharma,
Rebecca J. Thompson, Waraporn Imruetaicharoenchoke, Martin L. Read,
Kristien Boelaert, Christopher J. McCabe, Vicki E. Smith
Institute of Metabolism and Systems Research, University of Birmingham,
Birmingham, UK
Correspondence: Vicki E Smith (v.e.smith@bham.ac.uk)
Thyroid Research 2017, 10(Suppl 1):O2
Background
Radioiodine imaging, cell ablation and treatment of metastases in
thyroid cancer rely on the presence of a functional sodium iodide
symporter (NIS) in the basolateral plasma membrane (PM) of thyro-
cytes. Augmenting NIS PM localisation represents an important thera-
peutic strategy for increasing radioiodine delivery. We previously
described a mechanism by which NIS is internalised by pituitary
tumor-transforming gene-binding factor (PBF) in thyroid cells, signifi-
cantly reducing radioiodine uptake. Importantly, we demonstrated
that PBF phosphorylation at Y174 by Src kinase mediated NIS repres-
sion, which could be rescued by the Src family kinase (SFK) inhibitor
PP1.
Methods
We have now replicated these findings in breast cancer cells, further
elucidated the mechanism of repression and identified a more po-
tent inhibitor of PBF-pY174.
Results
In MCF-7 and MDA-MB-231 breast cancer cells with either exogenous
or all-trans retinoic acid/dexamethasone-induced NIS expression, PBF
significantly repressed radioiodine uptake and this was reversible
with PP1 treatment. PBF-Y174 is also a critical part of an endocytosis
motif and mutation results in PM accumulation. Mutation of a pre-
dicted Src consensus sequence (EEN170-172AAA) abrogated pY174
and radioiodine uptake repression, confirming Src-dependent Y174
phosphorylation and demonstrating that NIS repression is mediated
by phospho-PBF and not PM-bound PBF. Treatment with the SFK in-
hibitor dasatinib potently inhibited PBF-pY174 and restored radioio-
dine uptake. In the presence of dasatinib-resistant Src (T341I),
dasatinib no longer rescued PBF repression of NIS, indicating that Src
and no other SFK mediates PBF phosphorylation.
Conclusions
Taken together, these data suggest that Src inhibition can effectively
enhance radioiodine uptake in multiple tumour types, with implica-
tions for improving outcomes in thyroid cancer and utilising NIS for
the treatment of other tumours.
O3
Comparative analysis of human and mouse expression data
identifies proto-oncogene PTTG- and PBF-associated genes in
thyroid cancer
Martin L. Read1, Jim C. W. Fong1, Waraporn Imruetaicharoenchoke1,
Bhavika Modasia1, Hannah Nieto1, Alice Fletcher1, Rebecca Thompson1,
Neil Sharma1, John C. Watkinson2, Andrew S. Turnell3, Kristien Boelaert1,
Vicki E. Smith1, Christopher J. McCabe1
1Institute of Metabolism and Systems Research, University of
Birmingham, Birmingham, UK; 2University Hospitals Birmingham National
Health Service Foundation Trust, Birmingham, UK; 3Institute of Cancer
and Genomic Sciences, University of Birmingham, Birmingham, UK
Correspondence: Martin L. Read (m.l.read.20@bham.ac.uk)
Thyroid Research 2017, 10(Suppl 1):O3
Background
Whilst the proto-oncogene PTTG and its binding partner PBF have
been shown to be up-regulated in differentiated thyroid cancer,
there is a paucity of information regarding their co-expression and
specific roles in tumour progression. In particular, PTTG and PBF have
both been reported to modulate the tumour suppressor p53, whose
activity is impaired in most human cancers. Therefore, the role of
PTTG and PBF in thyroid tumorigenesis may involve disruption of
p53 pathways that are central to DNA-damage repair (DDR), cell
growth and apoptosis.
Methods
In the present study we investigated the association of PTTG and
PBF with p53-related genes in the TCGA thyroid cancer dataset, as
well as in a bi-transgenic murine model (Bi-Tg) overexpressing PTTG
and PBF specifically in the thyroid gland.
Results
Characterisation of primary murine Bi-Tg thyrocytes revealed that co-
expression of PTTG and PBF caused extensive repression of DDR
genes (39/82 genes; P < 0.05). Of these, 31 genes were down-
regulated >1.5-fold, including genes with key roles in maintaining
genomic integrity such as Brca1. Irradiation exposure to increase
intracellular p53 further showed significant differences in overall DDR
gene expression (n = 82 genes) between irradiated Bi-Tg and wild-
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type thyrocytes (P = 2.4 × 10−4) that was greater than either PBF-Tg
(P = 1.5 × 10−3) or PTTG-Tg thyrocytes (P = NS). By comparison in the
TCGA dataset, there were striking correlations with PTTG and PBF in
well-characterised p53-related gene panels (P < 0.05; 82–96 genes
per panel; n = 322 unmatched TCGA tumour samples). Importantly,
nearly half of the significant DDR gene alterations in Bi-Tg thyrocytes
were also present in TCGA comparing samples with either low
or high PTTG/PBF mRNA levels. Furthermore, the overall survival
(P = 0.0002) and disease-free survival (P = 0.02) was poorer for TCGA
individuals with high tumoural PTTG/PBF expression (n = 20) than for
all other patients (n = 255).
Conclusions
Altogether our findings provide important insights into the
association of p53-related genes with PTTG and PBF in thyroid
tumourigenesis.
O4
Graves’ disease with fluctuating thyroid status and hypothyroidism
with positive anti-TSH receptor antibody levels - distinctive
autoimmune side-effects following alemtuzumab therapy for
multiple sclerosis
Nadia Pariani1, Mark Willis2, Ilaria Muller3, Sarah Healy2, Taha Nasser2,
Joanne Jones4, Krishna Chatterjee1, Colin Dayan3, Neil Robertson2,
Alasdair Coles4, Carla Moran1
1Wellcome-MRC Institute of Metabolic Science, University of Cambridge,
Cambridge, UK; 2Institute of Psychological Medicine and Clinical
Neuroscience, Cardiff University & University Hospital of Wales, Cardiff,
UK; 3Department & Institute of Molecular & Experimental Medicine,
Cardiff University, Cardiff, UK ; 4Department of Clinical Neurosciences,
University of Cambridge, Cambridge, UK
Correspondence: Carla Moran (cm682@medschl.cam.ac.uk)
Thyroid Research 2017, 10(Suppl 1):O4
Background
Alemtuzumab, a highly effective, newly-licensed, treatment for
multiple sclerosis (MS), is associated with autoimmune side-effects -
notably Graves’ disease (GD) with a reportedly indolent course.
Aim
To determine the type, frequency and course of thyroid dysfunction
(TD) in a cohort of alemtuzumab-treated MS patients in Cambridge &
Cardiff.
Methods
Case records of alemtuzumab-treated patients who developed TD
were reviewed.
Results
Overall, 40% (102/249; 81 F, 21 M) of alemtuzumab-treated patients
developed TD; 71 cases with follow up data (median 5 yrs; range 5–
198 months) post TD were analysed. Mean TD onset was 23 months
(range 2-107mths) following the most recent dose of alemtuzumab;
most (89%) occurred within 3 years. GD, defined as hyperthyroidism
with positive anti-TSH receptor antibody (TRAB) levels, occurred most
commonly (47/71; 66%). 9 of these (20%) showed fluctuating thyroid
status, (transitioning from hypo to hyperthyroidism or vice versa). 27
GD patients completed a course of anti-thyroid drug (ATD) therapy,
with 48% (13/27) relapsing and 52% (14/27) in remission after drug
withdrawal. 3 cases of thyroiditis and 7 cases of anti-TPO antibody
positive hypothyroidism were identified; in 8 cases, hypothyroidism
with negative anti-TPO but positive TRAB was recorded. In 5 thyro-
toxic and 1 hypothyroid case, antibody testing is outstanding.
Conclusion
In our ascertained cohort, GD was the commonest cause of
alemtuzumab-induced TD, with post therapy relapse being compar-
able to conventional GD. Fluctuating thyroid status in alemtuzumab-
induced GD (20% of cases), together with an unexpectedly high
occurrence of anti-TPO negative, TRAB-positive hypothyroidism,
suggests that both stimulating and blocking anti-TSH receptor anti-
bodies develop in this context.
O5
Controlled Antenatal Thyroid Screening (CATS) Study II; (i) Effect of
treatment of suboptimal gestational thyroid function (SGTF) on
children’s behaviour at age 9
Charlotte Hales1, Peter Taylor1, Sue Channon2, Kirsten McEwan2,
Aled Rees1, John Gregory1, Ilaria Muller1, Mohd S Draman1, Colin Dayan1,
Kate Langley3, Anita Thapar3, John Lazarus1 and Marian Ludgate1
1Thyroid Research Group, Cardiff University School of Medicine, Cardiff,
UK; 2Institute of Primary Care & Public Health, Cardiff University School
of Medicine, Cardiff, UK; 3Institute of Psychological Medicine and Clinical
Neurosciences, Cardiff University School of Medicine, Cardiff, UK
Correspondence: Charlotte Hales (halesc2@cardiff.ac.uk)
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Background
Many studies have investigated the effects of maternal SGTF on cog-
nition but little is known about its impact on behaviour. We ad-
dressed this question using mother/child pairs from the CATS study,
at time of consent participants were randomised and some received
levothyroxine therapy for SGTF from 12 weeks gestation. In CATS II,
120 from the treated and 106 from the untreated participated, as
well as 244 from the normal thyroid function group (GTF).
Methods
When children were aged 9 behaviour was assessed by maternal re-
ports using, The Strengths and Difficulties Questionnaire (SDQ), Child
ADHD Questionnaire and Social Communication Questionnaire (SCQ);
higher scores indicated more problems. Primary analysis used a
MANCOVA, firstly with SGTF groups merged, and secondly by individ-
ual group. Secondary analysis explored fT4 during pregnancy and
offspring behaviour; all analyses were Bonferroni corrected.
Results
The merged SGTF group had fewer peer problems (SDQ) (p = 0.008),
but more ADHD overactivity problems (p = 0.020) than the normal
GTF group. The analysis of the three groups revealed that
treated SGTF scored higher than normal GTF (for ADHD over-
activity p = 0.024) and the untreated SGTF (for SCQ, p = 0.047). ADHD
overactivity was positively correlated to fT4 at six weeks post initiation
of therapy. Children of over-treated mothers (fT4 > 17.7pmol/L) had
higher scores for ADHD overactivity compared to the rest of the study
group (p = 0.008).
Conclusion
Treatment of SGTF may exacerbate ADHD overactivity difficulties e.g.
11% of treated had scores >2SDs above the mean compared with
4% in normal and untreated. The analysis supports recent literature
that SGTF over-treatment may have a negative effect and requires
close monitoring throughout pregnancy.
P1
Increased all-cause mortality, rehospitalisation rate and
cardiovascular morbidity in hospitalised hyperthyroid patients – a
nested case-control study
Barbara Torlinska1, Jayne Franklyn1, Jamie Coleman2, Kristien Boelaert1
1Institute of Metabolism and Systems Research, University of
Birmingham, Birmingham, UK; 2Institute of Clinical Sciences, University of
Birmingham, Birmingham, UK
Correspondence: Barbara Torlinska (b.torlinska@bham.ac.uk)
Thyroid Research 2017, 10(Suppl 1):P1
Background
Thyroid dysfunction (TD) often runs an indolent course and may remain
undiagnosed for prolonged periods. Most subjects are treated as out-
patients; effects of TD on hospitalised individuals are poorly studied.
We set out to determine long-term influences of hyperthyroidism in a
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large cohort of inpatients evaluating their hospitalisation frequency, co-
morbidities and all-cause mortality.
Methods
A nested case-control study was conducted using a cohort admitted
to a large tertiary centre (2007–2012). 671 hyperthyroid subjects
were identified, matched (1:4) by age, gender and year of admission
with hypo- and euthyroid inpatients and followed until 31/12/2015.
Results
A total of 31,400 person-years were analysed in 5,979 inpatients.
There were 2,175 (36.4%) deaths. Hyperthyroidism was associated
with a significant increase in all-cause mortality compared to hypo-
and euthyroid inpatients (HR = 1.2 [95% CI:1.02–1.33], P = 0.03 and
1.3 [1.10–1.44], P = 0.001). Additionally, hyperthyroid inpatients were
more frequently re-hospitalised (4.0 [3.5–4.5]) compared with con-
trols in both groups (AORHo = 2.1, P = 0.003; AOREu = 4.8, P < 0.001).
They were more frequently admitted for circulatory conditions (CVD)
(NHr = 230, 34.3%; NHo = 711, 27.1%, AORHo = 1.5 [1.2–1.8], P < 0.001;
NEu = 601, 22.4%, AOREu =1.9 [1.6–2.3], P < 0.001) while respiratory
admissions were more common in hyperthyroid (N = 119, 17.7%)
when compared with euthyroid (N = 357, 13.3%, AOR = 1.4 [1.1–1.8],
P = 0.003) but not different from hypothyroid subjects; proportions of
patients admitted for nervous and digestive causes were not signifi-
cantly different. When considering recorded comorbidities, CVD was
more frequent in hyperthyroid inpatients (NHr = 457, 68.1%) than
matched controls (NHo = 1,679, 64.0%, AORHo = 1.3 [1.1–1.6], P = 0.007;
NEu = 1,442, 53.7%, AORHo = 2.2 [1.8–2.8], P < 0.001) and presented more
frequently with atrial fibrillation (NHr = 207, 30.8%; NHo = 441, 16.8%,
AORHo = 2.6 [2.1–3.2], P < 0.001; NEu = 339, 12.6%, AOREu = 3.6 [2.9–4.5],
P < 0.001) or heart failure (NHr = 105, 15.6%; AORHo = 1.5 [1.2–1.9],
P = 0.002; AOREu = 2.6 [2.0–3.4], P < 0.001).
Conclusion
We conclude that hyperthyroidism in hospitalised patients is associ-
ated with additional health and economic burdens, significantly in-
creasing likelihood of re-hospitalisation, cardiovascular morbidity and
all-cause mortality.
P2
Controlled Antenatal Thyroid Screening (CATS) Study II; (ii) Effect
of treatment of suboptimal gestation thyroid function (SGTF) on
children’s cognition at age 9
Charlotte Hales1, Peter Taylor1, Sue Channon2, Kirsten McEwan2, Lei Zhang1,
Ameen Bakhsh1, Michael Gyedu1, Aled Rees1, Onyebuchi Okosieme1,
John Gregory1, Ilaria Muller1, Mohd S Draman1, Colin Dayan1, John Lazarus1,
Marian Ludgate1
1Thyroid Research Group, Cardiff University School of Medicine, Cardiff,
UK; 2Institute of Primary Care & Public Health, Cardiff University School
of Medicine, Cardiff, UK
Correspondence: Charlotte Hales (halesc2@cardiff.ac.uk)
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Background
The Controlled Antenatal Thyroid Screening (CATS) study was the
first randomized controlled trial to investigate the effect of antenatal
thyroid screening and maternal levothyroxine treatment on child-
hood cognition, evaluated at 3 years of age. Although CATS did not
show treatment benefits, the childhood assessment may have been
undertaken too early for differences to be apparent.
Methods
In the present study cognition was re-assessed in offspring of the
Welsh CATS cohort aged 9 years using the WISC-IV (IQ). Groups com-
prised children of mothers with normal gestational thyroid function
(GTF, n = 233) and those of mothers with treated (n = 118) and un-
treated (n = 101) SGTF, i.e. TSH in the highest 2.5% and/or fT4 in the
lowest 2.5%. Analysis included a regression to explore the odds of
IQ < 85 (1SD below the mean). A secondary analysis explored chil-
dren’s Thr92Ala polymorphism and this was compared to maternal
thyroid status.
Results
There was no difference in proportion of children with IQ < 85 be-
tween children of women with SGTF (10%) and normal GTF (6.4%)
(p = 0.59) or between treated (8.5%) and untreated (11.9%) SGTF re-
sults (p = 0.29). Children homozygous for Thr92Ala and born to
mothers with low maternal fT4 levels, indicated a trend for IQ < 85
compared to the normal GTF group: OR = 2.90 (95%CI 0.49,17.30)
p = 0.24. Removing the treated group increased the odds of IQ < 85:
OR = 13.7 (95%CI 1.63,115) p = 0.01.
Conclusion
Our results do not support a beneficial effect of antenatal thyroid
screening on child cognition. One in seven of the population have
the Ala92Ala genotype and are more at risk of adverse effects of
SGTF. Further research is needed to clarify the impact of the
Thr92Ala polymorphism and its interaction with maternal thyroid
function on child cognition.
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Background
Hypothyroidism is the most common thyroid disorder. Genome-wide
association studies (GWAS) have identified variants in FOXE1 that are
associated with hypothyroidism, and PDE8B and CAPZB that are as-
sociated with TSH levels. However, the number of studies is limited
and replication studies are desirable.
Methods
Patients were identified from a study of the Genetics of Diabetes
Audit and Research Tayside (GoDARTS) recruited in Tayside, Scotland,
between January 1996 and March 2014. Electronic Medical records
(EMR)-derived phenotypes were ascertained and single-locus tests of
association were performed via logistic regression under the assump-
tion of an additive genetic model. Serum TSH levels were identified
in 16,769 patients of white ethnicity, 2,664 with hypothyroidism and
14,105 controls.
Results
A FOXE1 variant (rs925489) was associated with hypothyroidism
(OR = 0.77 [95%CI 0.71–0.83], P = 1.9 × 10−10). We found evidence that
other genetic variants previously associated with hypothyroidism were
also associated in this study. We found association with PTPN22
(rs6679677, P = 3.0 × 10−04), SH2B3 (rs3184504, P = 9.4 × 10−05), VAV3
(rs4915077, P = 9.9 × 10−03), and HLA (rs2517532, P = 7.5 × 10−05). The
analysis found the association of PDE8B (rs4704397, P = 1.0 × 10−22;
rs6885099, P = 1.1 × 10−32) and CAPZB (rs10799824; P = 8.2 × 10−12)
with serum TSH levels in euthyroid individuals. These genetic variants
explained 1.67, 1.57, and 0.82% of the variation of mean TSH levels
respectively.
Conclusions
Our results replicated the previously reported association of FOXE1
with hypothyroidism, and PDE8B and CAPZB with serum TSH levels,
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and emphasize the need for additional genetic studies in more
diverse population.
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Background
Familial medullary thyroid cancer (MTC) is associated with germline
RET mutations causing multiple endocrine neoplasia type 2 (MEN2).
The majority of germline RET mutations predisposing to MEN2 result
in single amino acid substitutions causing inappropriate constitutive
RET activation. However, some rare families with apparent MTC
predisposition do not have a detectable RET mutation (non-RET), sug-
gesting that further predisposing gene alterations remain to be
identified.
Methods
Here, we undertook exome sequencing studies in one family with
apparent predisposition to non-ret MTC and identified a novel ESR2
frameshift mutation, c.948delT; p.G318Afs*22, which segregated with
histological diagnosis following thyroid surgery. Sequencing of ESR2
in individuals with apparently isolated MTC identified a further novel
germline missense alteration, c.382G > C; p.V128L in a female who
developed MTC age 36 years.
Results
Functional assays showed that ESR2-V128L retained transcriptional
activity with a significant increase in luciferase activity in response to
ESR2-agonist DPN in HCT116 (3.7-fold; P < 0.01) and MCF-7 (1.8-fold;
P < 0.05) cells. In contrast, ESR2-G318Afs*22 was incapable of
inducing luciferase activity in either cell line (P = NS). Furthermore,
ESR2-G318Afs*22 failed to inhibit ESR1 driven luciferase activity in re-
sponse to either 17β-estradiol (E2) or ESR1-agonist PPT, or restrain
ESR1-driven proliferation of MCF-7 cells. In contrast, wild-type (WT)
ESR2 and ESR2-V128L inhibited ESR1-driven luciferase activity (>60%.
P < 0.01) and cell proliferation (>30%, P < 0.05). As RET expression is
known to be stimulated by oestrogen, we then determined the influ-
ence of ESR2 mutants on RET in E2- and PPT-treated HCT116 cells. In
contrast to WT ESR2, ESR2-G318Afs*22 was unable to oppose ESR1-
stimulation of the RET proto-oncogene at both the mRNA and pro-
tein level. Treatment with 4-hydroxytamoxifen was however capable
of inhibiting E2-induced RET mRNA expression in cells with ESR2-
G318Afs*22.
Conclusions
Together these data indicate an emerging role for ESR2 as a novel
susceptibility gene in non-RET MTC development, especially as ESR2-
G318Afs*22 was associated with elevated RET.
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Background
Causes of hyperthyroidism include Graves’ disease (GD), toxic multi-
nodular goitre and thyroiditis. British Thyroid Association guidelines
recommend specialist referral once hyperthyroidism is diagnosed.
TSH-receptor antibodies (TRAb) are more specific to GD than thyroid
peroxidase antibodies (TPOAb). Regional guidelines recommend
measuring TRAb in thyrotoxic patients. We aimed to assess TRAb use
regionally in newly diagnosed thyrotoxicosis.
Method
We conducted a retrospective case review of patients with newly de-
tected thyrotoxicosis from 1st March-31st August 2015 from 4 endo-
crinology centres. TSH, fT4, fT3, TPOAb and TRAb values; the
requester and date requested were recorded. Any thyroid uptake
scans done; and final diagnoses were noted.
Results
We analysed 209 records – 79% females (n = 166), 21% males
(n = 43); the average age was 50.5 (17–96). 88.6% had TRAb re-
quested. 76.2% requests were from endocrinologists, 15.7% from
GPs, 5.9% from Biochemistry, and 2.2% from other physicians.
56.2% had positive TRAbs. The commonest diagnosis was GD
(55.0%), followed by multinodular goitre (10.5%) and thyroiditis
(8.1%). GD was diagnosed using TRAb in 81.7%; and using thyroid
uptake scans in 6% (n = 7). 2 patients had clinical features; in 12
patients, the reason for favouring a GD diagnosis was unclear. 19
patients (9%) were not referred to endocrinology. Average time be-
tween detection of thyrotoxicosis and TRAb request was 40 days
(32–57 days). Time to TRAb request was shorter (average 9 days) if
requested prior to referral to an endocrinologist. This lag was be-
cause most TRAb requests were only requested after referrals were
received and reviewed by endocrinologists.
Conclusions
TRAb is commonly used regionally with good sensitivity and specifi-
city. We propose that it should be added on by biochemistry labs in
all newly thyrotoxic patients, as this could expedite diagnosis, mini-
mising use of inappropriate antithyroid medications. Availability of
results before endocrinology consultations would also facilitate
prompt treatment and better communication with patients.
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Background
The thyroxine absorption test is an established test to investigate the
cause of persistently raised TSH in patients on levothyroxine. We re-
view our experience with a modified form of this test in our clinical
setting.
Method
Patients with persistently raised TSH despite adequate thyroxine
dose and admitting good compliance were offered the test. They
were advised to fast and bring their own medication. A recent ECG,
medical history (including medications) was reviewed. Bloods were
taken for a baseline FT4, FT3 and TSH along with vitamin B12, folate,
ferritin, iron, transferrin, vitamin D, SHBG, coeliac screen and gastric
parietal antibodies.
A single (weekly) dose of levothyroxine calculated as [1.6 × weight
(kg) × 7 μg] was given orally under direct observation and FT4 and
TSH re-measured at 2 hours. Thereafter FT4 and TSH were measured
weekly (trough) and levothyroxine administered under observation.
An increase in FT4 at 2 hours by ≥50% following initial dose indi-
cated adequate GI absorption. Test was terminated once TSH fell
within the normal range. In patients where TSH was not at target
despite evidence of adequate absorption at 4 weeks, the levothyrox-
ine dose was increased to [2.0 × weight (kg) × 7 μg] weekly for
2 weeks; if TSH still remained elevated; the same dose was divided
and given as twice weekly for another 2 weeks. TFT results after
6 months or more were collected on the patients to check the effect
of thyroxine absorption test on long term compliance.
Results
Fourteen patients (two male, twelve female) with a mean age of
41 years (16–74), and weight 89 kg (53–124) underwent the test.
Cause of hypothyroidism was autoimmune in 8, total thyroidectomy
in 5 and congenital hypothyroidism in 1. Before testing, mean daily
levothyroxine dose was 209 μg/day (range: 100–300). In 9 there was
adequate absorption of levothyroxine and TSH normalised in 4 weeks
confirming poor compliance. In one patient TSH normalised after re-
ceiving the higher dose while two patients required higher amount
in divided dose to normalise TSH. One patient on continuous ambu-
latory peritoneal dialysis had inadequate FT4 response and failed to
normalise TSH at 8 weeks. TSH however normalised following renal
transplantation. Malabsorption due to total pancreatectomy was the
cause of TSH non-suppression in one. TFT results available on 10
patients, 6 months or more after the test showed that 70% of the
patients were maintaining TSH within normal range.
Conclusion
Thyroxine absorption test was useful in differentiating poor compli-
ance from other causes of persistently raised TSH. Some patients
who fail to suppress TSH after 4 weeks may require a higher dose of
levothyroxine administered once or twice weekly. Splitting dose as
twice weekly may be useful as in some individuals as t1/2 may be
shorter. Offering continuation as once or twice weekly dose may help
improve compliance over long term.
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Background
Identification of the cause of thyrotoxicosis is important as this trans-
lates to different treatments and prognosis. Using the current NICE
clinical knowledge summary (CKS), BTA guidelines for the use of
thyroid function tests, and a recent clinical review by B Vaidya et al
(2014), audit standards for appropriate diagnosis of thyrotoxicosis
were established.
Methods
All new patients at the hospital thyroid clinic in January 2015 were
screened. Data was gathered from referral letters, clinic notes, and
hospital information system. 37 patients were eligible.
Results
Treatment was initiated by the GP at the time of diagnosis in 13 of
the 37 (35.1%). 19 patients had thyroid antibodies checked (51.35%)
however only 1 of the 19 had TRAb included (5.55%). At initial endo-
crine OPA 32 of 36 had their TRAb checked (88.9%) and 3 of 35
(8.5%) had an RIUS or USS ordered.
Conclusions
51% of GPs ordered thyroid antibodies, but only 1 patient had TRAb
requested, suggesting that GPs were not aware of the benefit of
measuring TRAb (as the diagnostic hallmark of Graves) or did not
have access to this test. The NICE CKS does not ask the primary care
physician to measure TRAb, although most clinical experts suggest
its measurement on diagnosis of thyrotoxicosis. As TRAb was usually
only ordered at the first outpatient appointment, only 8% of patients
had RIUS/USS ordered at their first hospital appointment. 35% of pa-
tients had carbimazole initiated by GPs. This has implications for
diagnosis and long-term management, especially in the absence of
appropriate antibody testing and mean time from referral to first ap-
pointment of 35 days. A proposed change in our pathway is the
automatic addition of TRAb testing in all newly detected cases of
thyrotoxicosis when noted by our laboratory.
P8
Iodine deficiency amongst pregnant women in South-West
England
Bridget A. Knight1, 2, Beverley M. Shields1, Elizabeth Pearce3,
Lewis Braverman3, Xuemei He3, Rachel Sturley4, Bijay Vaidya5
1NIHR Exeter Clinical Research Facility, University of Exeter Medical
School, Exeter, UK; 2R&D Department, Royal Devon and Exeter NHS
Foundation Trust, Exeter, UK; 3Section of Endocrinology, Diabetes &
Nutrition, Boston University School of Medicine, Boston, MA, USA;
4Department of Women’s Health, Royal Devon and Exeter NHS
Foundation Trust, Exeter, UK; 5Department of Endocrinology, Royal
Devon and Exeter NHS Foundation Trust, Exeter, UK
Correspondence: Bijay Vaidya (B.Vaidya@exeter.ac.uk)
Thyroid Research 2017, 10(Suppl 1):P8
Background
Iodine is important for thyroid hormone synthesis, and iodine defi-
ciency in pregnancy may impair foetal neurological development.
The UK population is generally thought to be iodine sufficient; how-
ever recent studies have questioned this assumption. The WHO rec-
ommends the optimum median urinary iodine concentrations (UIC)
as 150-249 μg/l in pregnancy. Our study aimed to explore the preva-
lence of iodine deficiency in a cohort of pregnant mothers from
South-West England.
Methods
Urine samples were obtained from 308 women participating in a
study of breech presentation in late pregnancy. They had no known
thyroid disease and a singleton pregnancy at 36–38 weeks gestation.
Samples were analysed for UIC. Baseline data included: age, parity,
smoking status, ethnicity, BMI at booking, vitamin use, and validated
dietary questionnaire. There was no difference in median UIC
between women with (n = 156) or without (n = 152) a breech pre-
sentation (p = 0.8) so subsequent analyses were carried out as a
combined group.
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Results
Participants had a mean (SD) age 31(5) years, median (IQR) BMI
24.4(22.0, 28.3) kg/m2, 41% were primiparous, 10% smoked during
pregnancy, 34% took iodine (>140 μg/pill) containing vitamins. 96%
were Caucasian. Median (IQR) UIC was 88.0 (54.1, 157.5) μg/l, which
is consistent with iodine deficiency by WHO criteria. A total of 224/
308 (73%) of women had UIC values <150 μg/l. Increasing milk intake
was associated with higher UIC (p = 0.003). There was no difference
in median (IQR) UIC between those women who took iodine contain-
ing vitamins (n = 106) and those who did not (n = 202): 88.5(54.5,
170.5) vs 88.0 (53.8, 150.0) μg/l, p = 0.6. There was no correlation
between median UIC and TSH (p = 0.6) or FT4 (p = 0.1).
Conclusion
Iodine deficiency in pregnancy is common in South-west England.
Further research is needed to develop optimum prevention and
treatment strategies.
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